Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources
|
|
- Rachel Collins
- 8 years ago
- Views:
Transcription
1 Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources James Charnetski, Practice Leader Commercial Analytics & Effectiveness Quintiles Integrated Healthcare Solutions Copyright 2014 Quintiles 1
2 The New World of Value-Based Healthcare In a perfect world payers would not buy drugs and pharma would not sell drugs. They would buy and sell what the drugs do; improve health outcomes. 2
3 The New World of Value-Based Healthcare What if we could measure the impact of medicines by the improved outcomes they enable? What if we could allocate the deployment and measurement of commercialization efforts by these outcomes? 3
4 Pharma: Greater focus on the patient & enhancing QOL We aspire to improve the health and wellness of people around the world Merck Our mission is to help people do more, feel better, live longer GSK Transforming the lives of patients biogen idec Our mission is to care and cure Novartis We re passionate about improving quality of life and healthcare globally Teva 4
5 Value-based Commercial Model Framework An Outcomes-Based Commercial Model Built Around Five Key Questions 1 Real world data & analytics help us understand which treatments actually are prescribed to patients defined by: Condition being treated Demographics (age, sex) Clinical characteristics Line of use in treatment cascade What Drugs Are Prescribed? What Are the Prescribing Behaviors? 3 Treatment guidelines & comparative effectiveness research (CER) help us understand which treatments should be prescribed to patients defined by: Condition being treated Demographics (age, sex) Clinical characteristics Line of use in treatment cascade What Drugs Should Be Prescribed? How to Alter Prescribing Behavior? 5 RWD collected on changes in prescribing patterns & patient outcomes Via EMR systems & registries Changes assessed & fed into performance management system Linked to changes in market share How to Assess Change & Measure Outcomes? 2 Real world data & analytics help us gain deeper insights on how physicians prescribing behaviors vary: By patient characteristics (clinical, demographic) By specialty (primary care, specialist) By geography 4 Real world data, analytics & IT combine to create tools to inform prescribing decisions, improve prescribing behavior Predictive modeling of outcomes based on current prescribing behavior Simulation of improved outcomes based on changed prescribing behavior 5
6 Agenda Overview of QEMR platform Influence on commercial applications Case study Impact on targeting & resource deployment 6
7 Profile & Key Benefits of Q-EMR Platform Over 36 Million Unique Patients in an Ambulatory Care Setting 652 MQIC Institutions* 39,900 Providers (M.D., D.O., D.P.M., PA-C, RN-NP) 49 States and DC Rich clinical information QOL measures PHQ (depression), HAQ (RA/arthritis) and Wong-Baker FACES (pain) scores Diagnostic tests, lab values & vital signs OTC recommendations Covers all insurance types Personal and family history of medical conditions; co-morbidities; lifestyle data 7
8 Influence on Commercial Applications EMR drives additional insights across a number of commercial applications Treatment pathway/patient journey Understand treatment selection by line of therapy within specific patient cohorts and specialty segments Achieve better patient outcomes Improving patient care using realworld QOL outcomes measures and engagement Market Sizing & Patient Segmentation Draw upon a wealth of patient clinical demographics to gain insights into market potential Commercial Deployment Align commercial resources to local market potential by disease state to improve the probability of commercial success Performance Tracking Fine-tune brand performance measurement activities across several patient and practice dimensions Prospective Market Research Connect with physicians and patients to further draw upon their treatment and therapy experience. 8
9 Case Study: Atrial Fibrillation 9
10 Case study Issue Understand if treatment selection in the A-Fib market is optimal based on certain patient risk factors Opportunity Identify and prioritize geographies where A-Fib treatment selection is suboptimal Action Deploy specific field-based resources and messaging within select geographies to drive the clinical benefits and value of newer therapy options on these patient populations 10
11 Inputs into Statistical Analysis Data Sources Q-EMR National network of ambulatory care offices 36+ million patients, 30,000 providers,» ~350K A-fib patients (Dx )» 1.1 million patients Cardiac Dysrhythmias Q-EMR / Truven Market Scan linked database 1.9 million Q-EMR patients linked to Truven claims» ~30K linked A-fib patients on anti-coagulant IMS prescriber-level data TRx at the 5-digit zip Physician specialty, decile and state Market Definition Warfarin, Pradaxa, Xarelto, Eliquis Key Data Elements Stroke risk assessment score (CHA2DS2-VASc). Contraindication for warfarin: (artificial heart valves, significant valve disease, severe renal failure, advanced liver disease, pregnancy) Clinical measures (e.g., BP, BMI, lipids) INR, prothrombin, and platelet levels Current and past therapies for anticoagulation, antihypertension, antiplatelet, and lipid-lowering: start/stop dates, cost/fill, compliance Current and past therapies for rate and rhythm control AF outcomes: Ischemic stroke, transient ischemic attack Anticoagulation side effects: Hemorrhage Patient characteristics and demographics (including state of residence), Provider specialty and decile Current product share at 3 digit zip level Concentration of top deciles at 3 digit zip level Time since AF diagnosis Other comorbidities 11
12 Claims vs. Rx-level information Source: Q-EMR, Truven, IMS Health 12
13 Brand Performance EMR + Rx-level data = a more accurate depiction of the A-Fib market ~53% of total prescriptions are written for A-Fib What Drugs Are Prescribed? 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 21.8M TRxs 11.7M TRxs 78% 71% Rx-level Rx-level (for Dx only) Warfarin Xarelto Pradaxa Eliquis Source: IMS Health, Q-EMR 13
14 A-Fib Brand Performance by Specialty Slower adoption of newer agents by PCPs in the management of A-Fib What Are the Prescribing Behaviors? 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 6.3M TRxs 4.9M TRxs 83% 55% Rx share for A-Fib (PCP) Rx share for A-Fib (Cards) Warfarin Xarelto Pradaxa Eliquis Source: IMS Health, Q-EMR 14
15 A-Fib TRx Performance by State Warfarin A-Fib State-level TRx Share ranges from 45%-92% What Are the Prescribing Behaviors? Evaluating product use by Dx from EMR data at the state and specialty level in conjunction with Rx-level claims data, we are able to estimate warfarin market share for A-Fib. Source: IMS Health, Q-EMR 15
16 What Are the Prescribing Behaviors? Does A-Fib treatment vary locally in NC? 9 local geographies had Warfarin use greater than the state average (65%), ranging from 67%-85% Source: IMS Health, Q-EMR 16
17 Are certain A-Fib patient types at higher risk? Warfarin patients are at greater risk of experiencing a bleeding or ischemic stroke event over newer therapy options. What drugs should be prescribed? Source: Q-EMR 17
18 A-Fib HR for Bleeding and Ischemic Stroke Events Both Xarelto and Pradaxa are superior to warfarin for reduction of bleeding risk. Pradaxa is superior to warfarin in the prevention of ischemic stroke. Ischemic Stroke 0.64** 0.94* Bleeding warfarin (n=20448) Xarelto (n=2517) Pradaxa (n=4524) * Xarelto vs. warfarin Rocket AF Study HR = 0.88 ( ) ** Pradaxa vs. warfarin RE-LY study HR = 0.65 Source: Q-EMR 18
19 Can future stroke event risk be reduced? Through predictive modeling, we estimate that ~30% of Warfarin A-Fib patients would benefit from an alternative therapy that would reduce their future risk of a stroke or bleed event. How to Alter Prescribing Behavior? n = 11.7M Prescriptions Source: IMS Health, Q-EMR 19
20 Patients, Pharma & the Health System all Benefit Patient outcomes improve with less overall reported events; brand share improves across newer and safer agents, and the overall costs of healthcare are reduced with the decline of more costly ischemic stroke events. How to Alter Prescribing Behavior? Source: IMS Health, Q-EMR 20
21 Treatment Model Summary In addition to less reported events and greater patient QOL, manufacturers also benefit via incremental gains in brand performance. How to Alter Prescribing Behavior? 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% A-Fib TRx Share N. Carolina Pre & Post Treatment Deficit 66% Current 40% Modeled Eliquis Xarelto Pradaxa Warfarin Source: IMS Health, Q-EMR 21
22 How to Alter Prescribing Behavior? Impact on targeting Local geographies were prioritized based on a combination of current treatment patterns and modeled results, incorporating other local health system and payer influences Identify geographic areas with high concentrations of targeted diagnoses with greatest upside potential for a comprehensive IDN/ACO cross stakeholder model Deliver prime targets for focused analysis on local market behaviors and opportunities for improvement 22
23 Impact on resource deployment How to Alter Prescribing Behavior? Field-based and other integrated channel resources were deployed locally to capitalize on the opportunity. Local market analytics and performance reporting monitor the impact of activities. Channels Analytics Solutions 23
24 Questions? 24
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationA Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationNOAC Reversal Agent Think Tank Follow-Up: Post Approval Safety & Effectiveness Pharmacoepidemiologic Approaches and Big Data
NOAC Reversal Agent Think Tank Follow-Up: Post Approval Safety & Effectiveness Pharmacoepidemiologic Approaches and Big Data Nancy Dreyer, PhD Chief of Scientific Affairs Copyright 2014 Quintiles FDA Feb
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationUnderstanding Diseases and Treatments with Canadian Real-world Evidence
Understanding Diseases and Treatments with Canadian Real-world Evidence Real-World Evidence for Successful Market Access WHITEPAPER REAL-WORLD EVIDENCE Generating real-world evidence requires the right
More informationAtrial Fibrillation Patient Survey Online survey of AFib Patients 65+ Exploring Experiences with the Diagnosis and Treatment of AFib.
Atrial Fibrillation Patient Survey Online survey of AFib Patients 65+ Exploring Experiences with the Diagnosis and Treatment of AFib September 2012 Objectives and Methodology Objectives Achieve better
More informationEXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION ISPOR 2013 WORKSHOP
More informationRx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationHow To Analyze Health Data
POPULATION HEALTH ANALYTICS ANALYTICALLY-DRIVEN INSIGHTS FOR POPULATION HEALTH LAURIE ROSE, PRINCIPAL CONSULTANT HEALTH CARE GLOBAL PRACTICE DISCUSSION TOPICS Population Health: What & Why Now? Population
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationBig Data and Healthcare Information. Ed Reiner Quintiles Transnational
Big Data and Healthcare Information Ed Reiner Quintiles Transnational About Me 30 years in the information sector McGraw-Hill Information Division Elsevier Science (Cardiosource, ScienceDirect) Medical
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationWhat You Need to KnowWhen Taking Anticoagulation Medicine
What You Need to KnowWhen Taking Anticoagulation Medicine What are anticoagulant medicines? Anticoagulant medicines are a group of medicines that inhibit blood clotting, helping to prevent blood clots.
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2016
Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationStroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures
Stroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures Apodi Healthcare Mathew s Practice, Sheffield. June & July 2013 This SPAF Integrated Care Clinic programme
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationCopyright 2009 SAS Institute Inc. All rights reserved. Success With Business Analytics in the New Pharmaceutical Commercial Model.
Copyright 2009 SAS Institute Inc. All rights reserved. Success With Business Analytics in the New Pharmaceutical Commercial Model. Emerging Commercial Models: Rethinking Analytics Deloitte Consulting LLP
More informationAFib (short for atrial fibrillation) is the most common type of irregular heartbeat, affecting literally millions of men and women
What is atrial fibrillation? AFib (short for atrial fibrillation) is the most common type of irregular heartbeat, affecting literally millions of men and women What is atrial fibrillation? AFib occurs
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationSurvey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation
Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation On the following pages are a number of questions asking about the conditions under which you would prescribe anticoagulation
More informationStroke/VTE Quality Measure Build for Meaningful Use Stage 1
Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationEMR Tutorial Acute Coronary Syndrome
EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationSwedish RWE a goldmine?
Swedish RWE a goldmine? How is Novartis using Swedish RWE to improve decision making? Madlaina Costa, Head Health Economics and Pricing, Novartis Sweden RWE in Europe, Amsterdam 3 rd June 2015 Swedish
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationReal World Data: How It s Used at a Medical Device Company
MD MEDICAL SAFETY Real World Data: How It s Used at a Medical Device Company Myoung Kim, Ph.D., MBA. Andrew Yoo, M.D., M.S. Epidemiology and Health Informatics Medical Devices Johnson & Johnson May 29,
More informationHigh Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
More informationTurning Big Data into a competitive advantage? Challenges and opportunities
Turning Big Data into a competitive advantage? Challenges and opportunities Presentation prepared for CIB Symposium by IMS Health Kris Bruynseels, Senior Principal, Technology and Services, IMS Health
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationAnticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions
Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran, rivaroxaban and apixaban and what are they used for?...2
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationEXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA. ISPOR Workshop, May 22, 2013
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA ISPOR Workshop, May 22, 2013 Agenda Introduction to linked claims-emr database Obesity case
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationMaking the Health Check work for you
Making the Health Check work for you Atrial Fibrillation and the GRASP toolkit (Guidance on Risk Assessment and Stroke Prevention ) Dr. Indira Natarajan Consultant Stroke Physician University Hospital
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationTreatments to Restore Normal Rhythm
Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationManagement of Antithrombotics with Procedures. Jordan Weinstein, MD
Management of Antithrombotics with Procedures Jordan Weinstein, MD Presenter Disclosure Information Cardiology Update 2013 I have no relevant financial interest and/or arrangement with industry. Novel
More informationA PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF)
A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects,
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationParallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets
Parallel Session 2 Five Pillars to succes A framework for approaching market research in Emerging Markets Steve Kretschmer, Ipsos, Turkey and Beyza Ozel, Novartis, Turkey 5 Pillars to Success: A Framework
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationAtrial Fibrillation (AF) March, 2013
Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one
More informationSAVAYSA (edoxaban) U.S. Opportunity
SAVAYSA (edoxaban) U.S. Opportunity February 17, 2015 Ken Keller President, U.S. Commercial DSI, Inc. Key Discussion Points Daiichi Sankyo, Inc. (DSI) in the U.S. SAVAYSA (edoxaban) U.S. Indication NOAC
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationIC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice
IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice Presenter Disclosure Information Paul Chan, MD FINANCIAL DISCLOSURE: None FUNDING FOR THE IC3 PROGRAM: Bristol-Myers Squibb / Sanofi
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationQuality Improvement in Primary Care Settings
Quality Improvement in Primary Care Settings Eboni Price Haywood, MD, MPH Chief Medical Officer, Tulane Community Health Medical Director, Tulane Community Health @ Covenant House Team Approach to Quality
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationPHARMACEUTICAL BIGDATA ANALYTICS
PHARMACEUTICAL BIGDATA ANALYTICS ANDINSIGHTS December 2013 Strategic Research Insights, Inc. 2013 Sources of Big Data in rpharmaceutical and Healthcare Industry Challenges with Big Data in Pharma Oncology
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationThe Patient Journey in High Resolution
The Patient Journey in High Resolution Innovating for a richer understanding of the patient journey By Jackie Ilacqua Tel +1 201-574-8079 Email jackie.ilacqua@ipsos.com 1 xx-xx-xx Achieving a rich, yet
More informationEdoxaban - Potential Game changer in oral anticoagulant market
Brochure More information from http://www.researchandmarkets.com/reports/2227884/ Edoxaban - Potential Game Changer in Oral Anticoagulant Market Description: Edoxaban - Potential Game changer in oral anticoagulant
More informationFrom Concept to Rapid Visualization a Data Analytics Case Study
From Concept to Rapid Visualization a Data Analytics Case Study Gregory Wozniak, PhD Director of Outcomes Analytics Health Outcomes Group American Medical Association The Journey Objectives Share experiences
More informationHow we use Big Data Analytics to Create Customer and Patient Intimacy
How we use Big Data Analytics to Create Customer and Patient Intimacy About Evariant The leading provider of a CRM platform based on a centralized healthcare data hub, analytics, and communications engine.
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationAtrial Fibrillation Centre
About this guide We have prepared this guide to help you to: learn about atrial fibrillation manage atrial fibrillation and reduce the risk of stroke find out about medicines and other treatment options
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationDelivering Real World Evidence. Canada Let s Get Real!
Delivering Real World Evidence from Electronic Medical Records in Canada Let s Get Real! Neil Corner Director, Real World Evidence, IMS Brogan Alison Dziarmaga Director, Real World Evidence, AstraZeneca
More informationRadiology Business Management Association Technology Task Force. Sample Request for Proposal
Technology Task Force Sample Request for Proposal This document has been created by the RBMA s Technology Task Force as a guideline for use by RBMA members working with potential suppliers of Electronic
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More informationUsing Health Information Technology to Improve Quality of Care: Clinical Decision Support
Using Health Information Technology to Improve Quality of Care: Clinical Decision Support Vince Fonseca, MD, MPH Director of Medical Informatics Intellica Corporation Objectives Describe the 5 health priorities
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationThe 4 Pillars of Clinical Integration: A Flexible Model for Hospital- Physician Collaboration
The 4 Pillars of Clinical Integration: A Flexible Model for Hospital- Physician Collaboration Written by Daniel J. Marino, President & CEO, Health Directions November 14, 2012 Originally published by Becker
More information